Digene to sell HPV (Human Papilloma Virus) test in Japan:
This article was originally published in Clinica
Executive Summary
Digene has received clearance in Japan to market its Hybrid Capture 2 HPV test for the detection of human papillomavirus, as a follow-up test to border line Pap smear results. The Gaithersburg, Maryland-based firm has also recently filed for US FDA approval to use the HPV DNA test in conjunction with the Pap smear as a primary screen for cervical cancer and its precursors in women age 30 and over.